Research
Research on Psilocybin-Containing Fungi
Rose Hill has teamed up with the University of Guelph to advance the scientific study of psilocybin-containing fungi.
By joining hands with the University of Guelph, a leader in agricultural science and research, Rose Hill hopes to uncover new perspectives into how these mushrooms can be used safely and effectively.
This collaboration is set to focus on two key projects.
Chemical Characterization and Standardization of P. Cubensis
This project consists of two primary objectives; the chemical characterization of selected strains of P. cubensis mushrooms, comparing their profiles when cultivated in a commercial facility in Jamaica and under controlled conditions at the University of Guelph. This part of the project will provide chemical profiles of each strain in both settings.
The second phase of this project will be to evaluate the mushroom material in a preclinical setting to compare the efficacy of each strain and compare this to pure psilocybin. This will evaluate the impact of whole mushroom preparations against purified psilocybin and provide preclinical data for these specific strains of P. cubensis.
A Pre-clinical Trials on the Study of the Effects of Psilocybin on the Autistic Brain.
This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.
The valproic acid (VPA) model of idiopathic autism will be used. This requires administration of VPA to pregnant dams. Offspring will be allowed to grow until postnatal day 24 after which they will be fed the mushrooms daily until day 58. During this time rats will be evaluated in a variety of behavioral tests. Systems function through in vivo electrophysiology will be assessed. At the end of the study, brains will be harvested, and RNA extracted.
Areas of Focus Include:
24
Days until postnatal day for observational study in offspring
58
Days of daily mushroom administration in the study
2
Phases in the Psilocybin research project
Working Together for Better Mental Health
Rose Hill has formed a partnership with the Canadian Center for Psychedelic Science. This collaboration seeks to merge the latest research with practical therapeutic methods. Dedicated to enhancing mental health care, the center’s approach is rooted in rigorous scientific research. Their goal is to develop safe and effective treatment methods, ushering in a new chapter in mental health treatment
Phase 1
This protocol is for a randomized, placebo-controlled
crossover phase 1 study of the safety and efficacy of low doses of psilocybin in healthy subjects with depressive symptoms who meet DSM-5 criteria for diagnosis of a mild to moderate Major Depressive Disorder (MDD ) and who are either unwilling to pursue standard treatment (psychotherapy and/or pharmacotherapy) or have previously been non-responsive to standard treatment.
This feasibility study will assess
whether microdosing has a short-term impact on participant ratings of depressive symptoms.
Phase 2
We are now recruiting participants who wish to join the next step of our work. This effort continues our partnership with the Canadian Center for Psychedelic Science. We aim to see how low-dose psilocybin might support those who struggle with depression.
Psychedelic Therapy for Primary Care: A Comprehensive Clinical Primer
Invited Commentary on Psychedelic Therapy: A Primer for Primary Care Clinicians
Psychedelic Space Efforts & Involvement
Mental Health Meets Psychedelics
Dr. Burton Tabaac explores the potential of psychedelics like LSD, DMT, psilocybin, and MDMA in treating mental health conditions such as PTSD, anxiety, depression, and addiction. This TEDx talk challenges societal perceptions and highlights the future of psychedelic therapy.
Dr. Burton Tabaac Testifies on Psychedelic Therapy in Nevada
Dr. Burton Tabaac briefs Nevada lawmakers on the therapeutic potential of psychedelics for PTSD, depression, and addiction treatment.
PHATHOM-Stroke: Exploring Psychedelics for Stroke Recovery
The PHATHOM-Stroke Project, led by Drs. Gül Dölen, Steve Zeiler, and John Krakauer, tests whether combining psychedelics with physical therapy in digitally enriched environments can restore motor function in stroke patients, even long after their stroke.